KRAS and colorectal carcinoma: Furthermore, another study reported an improved therapeutic response to AA in CRC patients with KRAS mutations, inhibiting KRAS phosphorylation activity and promoting KRAS detachment from the cell membrane and inhibiting various downstream enzymes involved in glycolysis [18].